Oncotype DX® is the only multigene breast cancer assay incorporated into 3 major clinical guidelines1-3
The Oncotype DX assay provides an individualized assessment of the magnitude of chemotherapy benefit and the likelihood of distant recurrence to inform adjuvant treatment decisions. Newly diagnosed patients with node-negative or node-positive, ER-positive, HER2-negative invasive breast cancer are eligible.1, 2, 4-7
1. National Comprehensive Cancer Network®. NCCN Clinical Practice Guidelines in Oncology™: Breast cancer. Version 2.2011. Available at: www.nccn.org. Accessed September 29, 2011.
2. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations.
3. Goldhirsch A, Wood W, Coates A, Gelber R, Thürlimann B, Senn H-J, and Panel members.
Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2011. Ann Oncol. 2011;22:1736-1747.
4. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor–positive breast cancer. J Clin Oncol. 2006;24:3726-3734.
5. Paik S, Shak S, Tang G,et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351:2817-2826.
6. Dowsett M, Cuzick J, Wale C, et al. Prediction of risk of distant recurrence using the 21-gene Recurrence Score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC Study. J Clin Oncol. 2010;28:1829-1834.
7. Albain K, Barlow W, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010;11:55-65.